证券代码：301093 证券简称：华兰股份 公告编号：2025-116 江苏华兰药用新材料股份有限公司 关于公司签署募集资金三方监管协议暨注销 部分募集资金专户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"或"华兰股份"）于 2025 年 8 月 25 日召开第六届董事会第四次会议，审议通过了《关于变更部分 募集资金专户的议案》。董事会同意公司将存放于募集资金专户（中国民生银行 股份有限公司北京分行，银行账号：632342624）的募集资金余额（实际金额以 资金转出当日募集资金专户余额为准）转存至招商银行股份有限公司上海四平 支行。同时董事会授权公司核心管理层办理本次变更部分募集资金专户的相关 事宜，包括但不限于募集资金专户的注销、开立、签署募集资金三方监管协议 等。截至本公告披露之日，公司已完成本次变更部分募集资金专户的相关事宜。 现将相关情况公告如下： 一、 募集资金基本情况 经中国证券监督管理委员会《关于同意江苏华兰药用新材料股份有限公司 首次公开发行股票注册的批复》（证监许可[2021]3020 ...

Company Overview - Hualan Pharmaceutical Materials Co., Ltd. is located in Jiangyin City, Jiangsu Province, and was established on June 4, 1992. The company went public on November 1, 2021. Its main business involves the research, production, and sales of packaging materials for injectable drugs [1]. Financial Performance - As of November 24, Hualan shares increased by 5.05%, trading at 47.66 CNY per share, with a transaction volume of 111 million CNY and a turnover rate of 1.53%. The total market capitalization is 7.826 billion CNY [1]. - The company's main revenue sources are: film-coated rubber stoppers (49.07%), conventional rubber stoppers (48.50%), and others (2.43%) [1]. Fund Holdings - Hualan shares are a significant holding in the Galaxy Fund, specifically in the Galaxy Kangle Stock A fund (519673), which reduced its holdings by 130,300 shares in the third quarter, now holding 225,500 shares, accounting for 4.88% of the fund's net value [2]. - The Galaxy Kangle Stock A fund was established on November 18, 2014, with a current size of 156 million CNY. Year-to-date returns are 18.83%, ranking 2266 out of 4209 in its category, while the one-year return is 13.28%, ranking 2596 out of 3982 [2]. Fund Management - The fund manager of Galaxy Kangle Stock A is Fang Wei, who has been in the position for 4 years and 200 days. The total asset size of the fund is 703 million CNY, with the best return during his tenure being -12.65% and the worst being -25.26% [3].

Core Points - Hualan Co., Ltd. announced a change in the legal representative of its subsidiary, Nanjing Renqing Mianqun Health Technology Co., Ltd., due to operational development needs [2] - The subsidiary has completed the industrial and commercial change registration and obtained a business license issued by the Nanjing Qinhuai District Administrative Service Management Office [2]

Core Viewpoint - Hualan Biological Engineering Co., Ltd. (SZ 301093) announced an investor meeting on November 18, 2025, where the company's Vice General Manager and Board Secretary Liu Xue participated in addressing investor inquiries [1] Financial Performance - For the first half of 2025, Hualan's revenue composition was 99.07% from the pharmaceutical manufacturing sector and 0.93% from other businesses [1] - As of the report date, Hualan's market capitalization stood at 7.7 billion yuan [1]

Group 1: Company Overview and Strategic Moves - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. has over 1,000 pharmaceutical clients across more than 40 countries, providing a market entry and customer connection channel for its subsidiary, Kema Biotechnology [2] - The company is entering the AI innovative drug research and development field, responding to the global trend where major pharmaceutical companies are integrating AI into their strategic core [2] - The investment in Kema Biotechnology is seen as the first step in the company's strategic layout in AI innovative drug R&D, aiming to enhance technical service capabilities and foster new growth curves [2] Group 2: Product Development and Regulatory Status - The transition of the pen-type injector aluminum cap to "A" status allows the company to provide an integrated supply capability for core components of pen-type injectors, enhancing its competitive edge [3] - This transition also establishes a self-controlled supply chain for high-end pharmaceutical packaging materials, which have historically been dominated by international companies [3] - The company aims to meet the growing demand for high-end pen-type injector packaging materials, positively impacting future operational performance [3] Group 3: Collaboration and Market Expansion - The collaboration with Ganli Pharmaceutical Co., Ltd. is progressing well, with the recent regulatory approval strengthening this partnership [3] - The company is actively expanding its customer base, with positive developments reported in this area [3] Group 4: Shareholder Confidence and Future Outlook - The controlling shareholder's intention to increase shareholding reflects confidence in the company's long-term investment value and stable future development [4] - The company will disclose its full-year performance for 2025 in its annual report, which will be available on the designated information platform [4]

| 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 法定代表人 | 刘雪 | 华一敏 | 证券代码：301093 证券简称：华兰股份 公告编号：2025-115 江苏华兰药用新材料股份有限公司 关于南京孙公司变更法定代表人并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 基于经营发展需要，江苏华兰药用新材料股份有限公司（以下简称"公司"）的 南京孙公司南京仁青眠曲健康科技有限公司（以下简称"南京仁青眠曲"）对其法定 代表人进行了变更。近日，南京仁青眠曲已完成工商变更登记手续，并取得由南京 市秦淮区政务服务管理办公室下发的《营业执照》。具体情况如下： 一、本次南京仁青眠曲变更情况 2025 年 11 月 18 日 二、南京仁青眠曲最新营业执照登记情况 | 名称 | 南京仁青眠曲健康科技有限公司 | | | --- | --- | --- | | 统一社会信用代码 | 91320104MAEUM7J69U | | | 类型 | 其他有限责任公司 | | | 住所 | 南京市秦淮区五福里 号 室 1 1079 ...

Core Viewpoint - As of November 14, a total of 96 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stocks with the longest consecutive net buying days are CITIC Bank and Galaxy Microelectronics, both having seen net buying for 13 consecutive trading days [1] - Other notable stocks with significant net buying days include Xinke Mobile, Mingchen Health, Hongrida, Xianggang Technology, Lianrui New Materials, Hualan Biological Engineering, Sunshine Nuohuo, and Zhongguang Optical [1]

Core Insights - The article discusses Hualan Co., Ltd.'s strategic move into the AI-driven innovative drug development sector through its subsidiary, Lingqing Zhizhi, which has signed investment agreements with several biotech firms [1][3]. Group 1: Investment and Partnerships - Lingqing Zhizhi plans to invest 20 million yuan (approximately 2.8 million USD) to acquire a 9.53% stake in Kema Biotechnology, gaining a board seat and preferential acquisition rights [3]. - The partnerships include companies like Shenzhen Jingtai and XtalPi, focusing on enhancing capabilities in AI-driven antibody design [3][4]. Group 2: Industry Context - The AI innovative drug development sector is gaining traction as traditional drug development faces challenges, often requiring ten years and one billion USD to develop a new drug [3]. - AI technologies, including machine learning and generative models, are seen as solutions to optimize the drug development process [3]. Group 3: Company Strategy and Market Position - Hualan Co., Ltd. specializes in the research, production, and sales of injectable drug packaging materials, positioning itself to leverage its extensive client base of over a thousand global pharmaceutical companies for AI drug development services [4]. - The company aims to enhance its technical service capabilities by recruiting top industry experts and diversifying its business team [4]. Group 4: Financial Performance - In the first three quarters of the year, Hualan reported revenues of 441 million yuan (approximately 61.5 million USD), a year-on-year increase of 4.36%, while net profit was 53.32 million yuan (approximately 7.4 million USD), up 2.06% [5]. - However, the third quarter saw a decline in both revenue and net profit, with revenues of 132 million yuan (approximately 18.5 million USD), down 4.72%, and net profit of 9.58 million yuan (approximately 1.3 million USD), down 37.2% [5].

Core Viewpoint - The company Hualan Co., Ltd. is entering the AI innovative drug development sector through its subsidiary Lingqing Zhizhi, aiming to leverage its existing client base in pharmaceutical packaging to create synergies and explore new growth opportunities [1][5]. Group 1: Investment and Partnerships - Lingqing Zhizhi has signed a capital increase agreement with several companies, including Shenzhen Jingtai and XtalPi, to invest in Kema Biotechnology [1][4]. - The company plans to invest 20 million yuan to acquire a 9.53% stake in Kema Biotechnology, which will also grant it a board seat and priority acquisition rights [3][4]. Group 2: Industry Context - Kema Biotechnology, founded in 2021, focuses on antibody design using generative AI models, aiming to innovate the traditional methods of antibody discovery [4]. - The AI innovative drug development sector is gaining attention as it offers a potential solution to the lengthy and costly traditional drug development process, which typically requires ten years and one billion dollars to develop a new drug [4]. Group 3: Business Strategy and Performance - Hualan Co., Ltd. is committed to enhancing its capabilities in AI innovative drug development by attracting top industry experts and building a diverse business team [4]. - In the first three quarters of the year, the company reported a revenue of 441 million yuan, a year-on-year increase of 4.36%, but experienced a decline in revenue and net profit in the third quarter [7].

Core Viewpoint - Hualan Co., Ltd. announces an investment in Kemaibiotechnology to enter the AI-driven innovative drug development sector, aiming to cultivate new growth opportunities [1][2] Investment Details - Hualan plans to invest RMB 20 million through its wholly-owned subsidiary, Lingqing Smart Pharmaceutical Technology Co., Ltd., acquiring a 9.53% stake in Kemaibiotechnology and gaining a board seat along with preferential acquisition rights [1][2] Company Background - Kemaibiotechnology, incubated by leading AI drug development firm Jingtai Technology, focuses on antibody design using generative AI models and has a strong data foundation from internal wet lab experiments [2][4] Industry Context - The pharmaceutical industry faces challenges with traditional drug development timelines and costs, prompting a shift towards AI as a core strategic element to enhance efficiency and reduce costs [2][3] - Major global pharmaceutical companies are increasingly integrating AI into their operations, with significant investments from tech giants like NVIDIA and Google [3] Market Potential - The global innovative drug market is projected to reach USD 1.08 trillion by 2024, with the antibody drug market exceeding USD 200 billion, highlighting substantial growth potential in AI-driven antibody design [4] Leadership and Expertise - Kemaibiotechnology's CEO, Dr. Wang Tianyuan, has extensive experience in AI and biopharmaceuticals, positioning the company to become a leader in AI-driven antibody drug discovery [4] Strategic Positioning - Hualan's investment is seen as a strategic move to leverage its established client base of over a thousand pharmaceutical companies across 40 countries, facilitating market access for Kemaibiotechnology [5][6] - The company aims to enhance its capabilities in AI innovative drug development by attracting top industry experts and fostering collaboration across its business units [6]